Business Wire

SpeeDx Receives Clearance for PlexPCR Respiratory Virus Test

Share

SpeeDx Pty. Ltd. today announced the clearance of the PlexPCR® RespiVirus* test from the Australian Therapeutic Goods Administration (TGA). The test utilises market-leading PlexPCR® technology to detect 11 viral respiratory-illness causing pathogens and allows laboratories to process more samples in an 8-hour shift compared to standard in-house test methods. The respiratory virus test includes automated reporting software to further improve laboratory productivity and speed up result reporting processes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005884/en/

The test PlexPCR(R) RespiVirus test utilises market-leading technology to detect 11 viral respirator ...

The test PlexPCR(R) RespiVirus test utilises market-leading technology to detect 11 viral respiratory-illness causing pathogens and allows laboratories to process more samples in an 8-hour shift compared to standard in-house test methods. (Photo: Business Wire)

“We are so pleased to be in a position to support Australian laboratories for what is already proving to be a very busy flu season,” said Colin Denver, SpeeDx CEO. “The workflow advantages afforded by PlexPCR® RespiVirus means more patient results can be reported over the course of a work day compared to standard technologies.”

Australian surveillance has recorded an unprecedented number of influenza cases in 2019 – with over four times the number of confirmed cases, compared with the first quarter year average.1 These initial numbers are well above those recorded in the early parts of 2017, where a record 233,453 cases were reported for the season.2 Laboratories were overwhelmed with the testing volumes during that time, and based on the unusual start of 2019, authorities are preparing for another potentially devastating season. The peak of the 2017 epidemic resulted in almost 30,000 hospital admissions and 745 deaths,3 now some experts are predicting up to 4,000 deaths could be possible across the 2019 season.4

The SpeeDx PlexPCR RespiVirus test detects important respiratory pathogens including Influenza A, Influenza B, Rhinovirus, Respiratory Syncytial Viruses (A & B), Human metapneumovirus, Adenovirus, and Human parainfluenza viruses 1, 2, 3 and 4. Results from the test can assist in appropriate patient care and community/outbreak management. The addition of PlexPCR RespiVirus to SpeeDx’s infectious disease test portfolio broadens the testing menu from the current suite of tests for sexually transmitted infections and antimicrobial resistance markers that include ResistancePlus® MG* and ResistancePlus® GC* supporting Resistance Guided Therapy for Mycoplasma genitalium and gonorrhoea respectively – and PlexPCR® VHS*, a multiplex lesion diagnostic test.

*not available in the U.S. or Europe.

About Respiratory Viruses

Respiratory tract infections (RTIs) are responsible for the majority of primary health care consults,5 causing high morbidity and mortality, particularly in young, elderly or immune-compromised populations.6 Viral agents cause up to 90% of RTIs - mainly human rhinoviruses (RhV), influenza viruses, and respiratory syncytial virus (RSV).7 Symptoms and duration include: common cold, sinusitis, pharyngitis, epiglottitis, and laryngotracheitis.8

Bacterial infection is difficult to established without performing diagnostic tests, thus empirical use of antibiotics is discouraged in treatment guidelines.9-13 Most uncomplicated infections will clear within 2-5 days without medical intervention.14,15 However, accurate detection of respiratory viruses is important in patient care, guiding therapy and infection control measures.16 Most importantly, distinguishing bacterial RTIs from viral is essential to avoid unnecessary antibiotic prescription. Pathogen identification is also a key component in management of acute respiratory infection outbreaks and pandemic preparedness strategies.16,17

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see https://plexpcr.com

References

  1. http://www.health.gov.au/internet/main/publishing.nsf/Content/cdnareport.htm
  2. Australian Government. 2017 Influenza Season in Australia. Information Brief (22 November 2017).
  3. http://www.who.int/mediacentre/factsheets/fs211/en/
  4. https://www.abc.net.au/news/2019-04-10/australian-flu-season-concerns-as-experts-urge-vaccinations/10987700
  5. Office of Population Censuses and Surveys. Series MB5,3. London: HMSO,1995
  6. http://www.erswhitebook.org/chapters/the-burden-of-lung-disease/
  7. Brittain-Long et al. Scand J Infect Dis 44(1):9-17
  8. https://www.ncbi.nlm.nih.gov/books/NBK8142/
  9. U.S. Department of Health and Human Services. Research Protocol – May 23, 2014 (Update)
  10. Harris AM et al. Annals of Int. Med. 164(6):425-435.
  11. https://www.nice.org.uk/guidance/CG69
  12. Woodhead et al. CMI 2011;17(6):1–24.
  13. Mahony JB. Clin. Microbiol. Rev. 2008;21(4):716–747
  14. Harris AM et al. Annals of Internal Medicine 164(6):425-435.
  15. https://www.nice.org.uk/guidance/CG69
  16. Ginocchio, CC & McAdam AJ. J Clin Micro. 2011; 49(9): S44–S48
  17. https://www.gov.uk/government/publications/acute-respiratory-infections-investigating-outbreaks-and-clusters-in-schools

Contact information

Madeline O’Donoghue
SpeeDx Global Marketing Manager
madelineo@speedx.com.au
+61 406 582 808

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CESTPress release

SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti

Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CESTPress release

In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs

Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CESTPress release

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp

Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family11.10.2019 02:00:00 CESTPress release

Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/ Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation) This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability. Development Background Advanced proces

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis10.10.2019 22:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005875/en/ “We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “These data suggest that filgotinib if approved, may play an important role in helping people living with rheumatoid arthritis achieve sustained, clinically meaningful responses.” “The

Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 201910.10.2019 20:05:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, October 26, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the con